Neil D. Gross, MD, FACS
@DrNeilGross
Followers
2K
Following
3K
Media
242
Statuses
2K
Professor, Head & Neck Surgery & Director of Perioperative Surgical Services. Expert in neoadjuvant trials. Husband, father and outdoor enthusiast.
Houston, TX
Joined May 2016
🗞️ today in @Nature! Incredible work led by @moranamit2 #OncSurgery @MDAndersonNews translating our findings using #neoadjuvant #immunotherapy in #skin #CSCC cancer @AACR @NEJM into a novel understanding of cancer biology.
3
6
53
Incredible honor! Congratulations Bob
Honored to join the NAM community and contribute to its wonderful mission to advance health and progress in medicine!
0
1
3
Poster time with international colleagues exploring novel ways to tackle advanced #skin #cancer @myESMO #ESMO25 Danny Rischin @PeterMacCC, @DrRahulLadwa @pahospital and Reinhard Dummer @Unispital_USZ @MDAndersonNews
0
1
14
So great to be back at @myESMO to present our trial-in-progress @NRGonc #HN014 testing neoadjuvant #immunotherapy in advanced, resectable #skin #CSCC cancer @Regeneron @CDNCancerTrials @TROGfightcancer #OncSurgery @MDAndersonNews #ESMO2025
0
7
22
Another great month of accrual to @NRGonc #HN014 #C-PRE for patients with advanced, resectable #skin #CSCC cancer. Excited for 🇦🇺 and 🇨🇦 to join the fight!🚀 @NCICancerCtrl
@TROGfightcancer
@CDNCancerTrials
@Regeneron
#OncSurgery
@MDAndersonNews
0
6
18
Very interesting discovery by @moranamit2 @MDAndersonNews. Cancer cells damage nerves, ➡️inflammation ➡️resistance to PD-1. Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy https://t.co/ygJsbzKSDG
@Nature @xrtGenomics @KaramLab @DrNeilGross
0
1
11
3
0
19
Virtual Tumor Board highlighting a young patient with neoadjuvant oral cavity SCC includes multidisciplinary perspectives from H&N, plastic surgery, pathology, radiation, and speech. Thoughtful insight from the patient is also included: https://t.co/UIBz4nQKZS
@OncoAlert #HNCSM
2
15
45
Hard to beat a trial with 92.5% or greater long-term OS across all arms!
Long-Term Follow-Up of E3311 (54 mo f/u) https://t.co/2nTvrTd2J7 ⭐️~15% (4/38) recurrence in pN1 in Arm A ⭐️No diff in PFS by smoking hx ⭐️No diff in PFS/OS for ≤1 mm) ENE vs no ENE ENE among intermed-risk assigned to PORT ⭐️Likely comparable PFS for 50Gy vs 60Gy PORT
0
0
8
Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus–Initiated Oropharynx Cancer | Journal of Clinical Oncology
ascopubs.org
This phase II trial of transoral surgery (TOS) with deintensified postoperative management in human papillomavirus (HPV)–associated oropharynx cancer (OPC) enrolled patients with resectable cT1-2...
2
7
17
Another negative (or a few have been weakly positive) adjuvant only anti-PD-(L)1 phase 3 solid tumour trial. Neoadjuvant is where it’s at with these agents!
More disappointing news in #HCC: Adjuvant pembrolizumab failed to beat surveillance in the global P3 #KEYNOTE-937 trial (NCT03867084). Merck disclosed the negative result quietly in an SEC filing. Not unexpected after #IMbrave050
0
8
40
MD Anderson is proud to be named #1 in the nation for cancer care in @USNews’“Best Hospitals” ranking. Read more: https://t.co/6DKYn4XAp5
#BestHospitals #EndCancer
10
63
210
Great to be in DC today @NRGonc giving an update on the progress of #HN014 #C-PRE for patients with advanced, resectable #skin #CSCC cancer. >100 sites activated in the US alone and accrual 🚀@NCICancerCtrl @TROGfightcancer @CDNCancerTrials @Regeneron #OncSurgery @MDAndersonNews
3
5
31
MATTERHORN: Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer https://t.co/GYoI0ebmnY
0
38
143
INNOVATE conference Naples - I love this think tank meeting! 2nd yr colleague Paolo Ascierto has hosted small but lively group of clinician researchers, clinical trialists and drug developers discuss an ALL #CANCER #NEOADJUVANT #immunotherapy approach. It is one of my favourite
0
3
52
Excited to see this work now out in JCO, important and unique long term data for the newest checkpoint combination. B7-H3 result could be practice informing & importantly targetable. Congrats to @Liz_htx03 for the incredible work to make this happen & Profs. Amaria & @JenWargoMD
Patients with advanced melanoma who received nivolumab + relatlimab before and after surgery had lasting results four years later. Biomarkers may help predict who benefits most. https://t.co/pxnMX5fEP9
#EndCancer
1
6
37
The @US_FDA has approved perioperative pembrolizumab adjuvant radiotherapy for adult patients with HNSCC with 🔹resectable, locally advanced disease 🔹who express PD-L1 with a CPS of at least 1, per an FDA-approved test. 🔗 https://t.co/z8IxZu74K6
#hnscc #oncology
onclive.com
The FDA has approved perioperative pembrolizumab adjuvant radiotherapy in resectable locally advanced HNSCC.
0
2
8